<DOC>
	<DOCNO>NCT00747344</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Ustekinumab treatment patient moderate severe psoriasis South Korea Taiwan .</brief_summary>
	<brief_title>A Phase 3 Trial Look Safety Effectiveness Ustekinumab Korean Taiwanese Subjects With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>This phase 3 , multicenter , randomize , placebo-controlled double-blind , parallel study subcutaneous injection placebo ustekinumab 45mg Taiwanese Korean patient moderate severe plaque psoriasis . Ustekinumab experimental medicine test see may useful treat moderate severe psoriasis . The patient receive either ustekinumab placebo week 0 week 4 , follow week 36 . Patients randomize ( study drug assign chance ) placebo cross ustekinumab 45mg group week 12 week 16 .The effectiveness ustekinumab compare placebo treat patient week 12 . Safety information collect week 36 . Patients randomized ustekinumab receive placebo week 12 maintain blind additional dose 45mg week 16 . This study conduct approximately 13 site South Korea Taiwan include approximately 120 patient approximately 60 patient country . This study `` blind . '' This mean neither study doctor know group place . However , case medical emergency , study doctor quickly find treatment group . You may get either ustekinumab placebo ( look like medicine study active ingredient ) start study . All patient study eventually receive Ustekinumab week 12 . Patients assign ustekinumab receive 45 mg subcutaneously week 0 , 4 16 ; placebo week 12 . Patiens assign placebo receive subcutaneous injection placebo week 0 4 ; crossover 45 mg ustekinumab week 12 16 . Duration study participation 36 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Must Taiwanese Korean ancestry live Taiwan South Korea , respectively Have diagnosis plaquetype psoriasis least 6 month prior first administration study agent ( patient concurrent psoriatic arthritis may enrol ) Have plaquetype psoriasis cover least 10 % total body surface area screen time first study agent administration PASI score 12 great time screen time first study agent administration Candidate phototherapy systemic treatment psoriasis ( either na√Øve history previous treatment ) Be able adhere study visit schedule protocol requirement Capable give informed consent prior study related procedure . Currently nonplaque form psoriasis Have current druginduced psoriasis Are pregnant nursing planning pregnancy ( men woman ) enrol study Have use investigational drug within previous 4 week 5 time half life investigational agent , whichever longer Have use biologic within previous 3 month 5 time half life biologic , whichever longer Have hospitalize past 3 year asthma , ever require intubation treatment asthma , currently require oral corticosteroid treatment asthma , require one shortterm course oral corticosteroid asthma within previous year Have history latent active granulomatous infection , include TB , histoplasmosis , coccidioidomycosis prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>CNTO 1275</keyword>
</DOC>